Displaying 21–30 of 184 research results
May 6, 2019 Eye On the Cure Research News
In a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
May 3, 2019 Eye On the Cure Research News
A video from a clinical trial of robot-assisted surgery demonstrates the potential benefits of robot-assisted subretinal injections.
May 2, 2019 Eye On the Cure Research News
Eloxx Pharmaceuticals is developing small molecules that permit read-through of point mutations that cause Usher syndrome 1F and 2A.
May 1, 2019 Eye On the Cure Research News
Francois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
Apr 30, 2019 Eye On the Cure Research News
Unlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
Apr 29, 2019 Eye On the Cure Research News
The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
Apr 16, 2019 Eye On the Cure Research News
The treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
Mar 23, 2019 Eye On the Cure Research News
Gyroscope Therapeutics, a gene-therapy development company in the UK, has launched the first gene therapy clinical trial for the dry form of age-related macular degeneration (AMD).
Mar 12, 2019 Eye On the Cure Research News
ProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
Feb 21, 2019 Eye On the Cure Research News
ReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.